MX2011011687A - Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer. - Google Patents
Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer.Info
- Publication number
- MX2011011687A MX2011011687A MX2011011687A MX2011011687A MX2011011687A MX 2011011687 A MX2011011687 A MX 2011011687A MX 2011011687 A MX2011011687 A MX 2011011687A MX 2011011687 A MX2011011687 A MX 2011011687A MX 2011011687 A MX2011011687 A MX 2011011687A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cancer
- combination
- relates
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con una combinación para el tratamiento del cáncer en donde la combinación muestra un efecto sinergístico. La combinación comprende radiación y al menos un inhibidor de la quinasa dependiente de ciclina (DKN) seleccionado de los compuestos de la fórmula I o su sal o solvato farmacéuticamente aceptables. La presente invención también se relaciona con un método para el tratamiento del cáncer, cuyo método comprende la administración a un paciente en necesidad de dicho tratamiento, una cantidad terapéuticamente efectiva de la combinación. La presente invención también se relaciona con el uso de un inhibidor de la CDK seleccionado de los compuestos de la fórmula I como un radiosensibilizador que mejora la eficacia de la radio terapia para el tratamiento del cáncer, particularmente cáncer de cabeza y cuello.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1174MU2009 | 2009-05-05 | ||
| US22452409P | 2009-07-10 | 2009-07-10 | |
| PCT/IB2010/051921 WO2010128443A1 (en) | 2009-05-05 | 2010-05-03 | Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011011687A true MX2011011687A (es) | 2012-02-29 |
Family
ID=42352216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011011687A MX2011011687A (es) | 2009-05-05 | 2010-05-03 | Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8895605B2 (es) |
| EP (1) | EP2427188B1 (es) |
| JP (1) | JP5730288B2 (es) |
| KR (1) | KR20120032476A (es) |
| CN (1) | CN102458398B (es) |
| AR (1) | AR079092A1 (es) |
| AU (1) | AU2010244101A1 (es) |
| CA (1) | CA2761182A1 (es) |
| IL (1) | IL216163A0 (es) |
| MX (1) | MX2011011687A (es) |
| NZ (1) | NZ596861A (es) |
| RU (1) | RU2011148954A (es) |
| TW (1) | TWI461194B (es) |
| WO (1) | WO2010128443A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201242597A (en) * | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
| TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
| MX2013014950A (es) | 2011-06-24 | 2014-04-16 | Piramal Entpr Ltd | Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. |
| WO2013105056A1 (en) * | 2012-01-13 | 2013-07-18 | Piramal Enterprises Limited | Pyrrolidine- substituted flavone derivatives for prevention or treatment of oral mucositis |
| CA3163776A1 (en) | 2012-08-03 | 2014-02-06 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| TWI680760B (zh) | 2013-07-12 | 2020-01-01 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合 |
| CN114478524A (zh) * | 2022-03-15 | 2022-05-13 | 江苏省肿瘤医院 | 1,8-萘啶类化合物及其应用 |
| CN114560799A (zh) * | 2022-03-15 | 2022-05-31 | 江苏省肿瘤医院 | 腈基取代苯基类化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (es) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7272193B2 (en) | 2003-06-30 | 2007-09-18 | Intel Corporation | Re-mapping trellis encoded data associated with a 2-bit constellation tone to data associated with a pair of 1-bit constellation tones |
| DK2046738T3 (da) * | 2006-06-21 | 2014-08-04 | Piramal Entpr Ltd | Enantiomerisk rene flavonderivativer til behandlingen af proliferative lidelser, samt processer til deres tilberedelse |
| PT2041121E (pt) | 2006-07-07 | 2011-09-12 | Piramal Life Sciences Ltd | Síntese enantiosselectiva de pirrolidinas substituídas com flavonas |
| WO2008139271A2 (en) | 2007-05-15 | 2008-11-20 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
-
2010
- 2010-04-19 TW TW099112188A patent/TWI461194B/zh not_active IP Right Cessation
- 2010-05-03 AU AU2010244101A patent/AU2010244101A1/en not_active Abandoned
- 2010-05-03 NZ NZ596861A patent/NZ596861A/en unknown
- 2010-05-03 MX MX2011011687A patent/MX2011011687A/es active IP Right Grant
- 2010-05-03 CA CA2761182A patent/CA2761182A1/en not_active Abandoned
- 2010-05-03 CN CN201080027763.5A patent/CN102458398B/zh active Active
- 2010-05-03 KR KR1020117029101A patent/KR20120032476A/ko not_active Application Discontinuation
- 2010-05-03 US US13/318,235 patent/US8895605B2/en active Active
- 2010-05-03 WO PCT/IB2010/051921 patent/WO2010128443A1/en active Application Filing
- 2010-05-03 RU RU2011148954/15A patent/RU2011148954A/ru unknown
- 2010-05-03 EP EP10724898.1A patent/EP2427188B1/en active Active
- 2010-05-03 JP JP2012509135A patent/JP5730288B2/ja active Active
- 2010-05-04 AR ARP100101501A patent/AR079092A1/es not_active Application Discontinuation
-
2011
- 2011-11-06 IL IL216163A patent/IL216163A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8895605B2 (en) | 2014-11-25 |
| IL216163A0 (en) | 2012-01-31 |
| WO2010128443A1 (en) | 2010-11-11 |
| RU2011148954A (ru) | 2013-06-10 |
| JP2012526098A (ja) | 2012-10-25 |
| EP2427188A1 (en) | 2012-03-14 |
| NZ596861A (en) | 2014-01-31 |
| CA2761182A1 (en) | 2010-11-11 |
| EP2427188B1 (en) | 2016-08-10 |
| KR20120032476A (ko) | 2012-04-05 |
| AU2010244101A1 (en) | 2012-01-12 |
| AR079092A1 (es) | 2011-12-28 |
| AU2010244101A2 (en) | 2011-12-22 |
| TW201039817A (en) | 2010-11-16 |
| US20120046334A1 (en) | 2012-02-23 |
| CN102458398B (zh) | 2014-07-16 |
| JP5730288B2 (ja) | 2015-06-10 |
| CN102458398A (zh) | 2012-05-16 |
| TWI461194B (zh) | 2014-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011011687A (es) | Flavonas sustituidas de pirrolidina como sensibilizadores de radio para su uso en el tratamiento del cancer. | |
| MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MY150697A (en) | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
| TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| CA2909625C (en) | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| TN2011000298A1 (en) | Compounds useful for inhibiting chk1 | |
| CA2908742C (en) | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
| MX2010004967A (es) | Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso. | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| WO2015035410A8 (en) | Cancer therapy | |
| WO2007081572A3 (en) | Inhibitors of checkpoint kinases | |
| WO2006074281A3 (en) | Inhibitors of checkpoint kinases | |
| WO2007136615A3 (en) | Combination cancer therapy | |
| MX2008016520A (es) | Medicamentos. | |
| WO2006074207A3 (en) | Inhibitors of checkpoint kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: PIRAMAL ENTERPRISES LIMITED.* |
|
| HC | Change of company name or juridical status |
Owner name: PIRAMAL ENTERPRISES LIMITED.* |
|
| FG | Grant or registration |